GACP, GMP, EU-GMP: Understanding Quality Standards for Medical Cannabis

Anyone interested in medical cannabis will sooner or later come across a flood of acronyms: GACP, GMP, EU-GMP.

These acronyms are not simply technical synonyms: they refer to distinct regulatory steps that a cannabis flower or extract must go through before it can legally be prescribed to a patient. Understanding where one begins and the other ends is essential for anyone involved in cultivation, processing, or importing—or for anyone simply seeking to understand why medical cannabis costs what it does.

What is GACP?

GACP means Good Agricultural and Harvesting Practices, or in French Good Agricultural and Harvesting Practices. This is an international quality standard, originally developed by the World Health Organization for medicinal plants in general, that sets guidelines for how a plant is grown, harvested, dried, and handled during the very first stages of processing.

For cannabis, GACP covers the entire agricultural aspect of the production chain: seed selection, growing conditions, irrigation, pest and mold control, harvesting techniques, drying, and post-harvest curing. The goal is twofold: to ensure product consistency from one growing cycle to the next, and to minimize the risk of contamination (pesticides, heavy metals, mold, microbial load…).

GACP is not specific to cannabis: it is the same set of standards that applies to other medicinal plants used in the manufacture of drugs. But in the case of cannabis, the flower itself very often constitutes the final pharmaceutical form, unlike most medicinal plants, which are always processed into extracts. This gives GACP compliance particular significance: a harvest becomes, directly, the medication administered to the patient. And if it is not properly managed, the patient pays the price.

GMP, BPF, EU-GMP: What's the Difference?

GMP, or GMP In French, this refers to the Good Manufacturing Practices, a pharmaceutical standard that is much broader and more rigorous than GACP.

It applies as soon as the plant material leaves the farm and enters the processing phase: final drying, grinding, extraction, formulation, packaging, labeling, storage, and distribution. GMPs do not apply solely to cannabis: they govern virtually all pharmaceutical products worldwide, from vaccines to pain relievers.

EU-GMP, or European GMPs, corresponds to the specific implementation of this standard within the European Union, as codified in the’EudraLex, Volume 4. It is significantly more stringent than the GMP standards applied in certain non-European jurisdictions—such as the Canadian GPP certification, for example—or the food/supplement-level GMP standards that govern a large portion of the cannabis industry in the United States.

European GMPs require pharmaceutical-grade manufacturing environments (cleanrooms), validated processes, continuous environmental monitoring, complete batch traceability, and, above all, the validation of each batch by a Qualified Person (QP), the person legally responsible for certifying that a batch meets the specifications before it is placed on the market.

This distinction has practical implications. A GMP-certified Canadian company, for example, cannot automatically sell its products in the EU: it must obtain separate EU-GMP certification, a process that typically takes 12 to 24 months and can cost anywhere from 500,000 euros to several million euros, depending on the size of the facility and the infrastructure already in place.

Where does GACP end, and where do GMPs begin?

This is the question that causes the most confusion, and European regulations address it directly. The’Appendix 7 of the EU GMP Guidelines, which focuses on the manufacture of herbal medicines, precisely defines the tipping point between the two standards.

In practice, GACP covers cultivation up to the point where the harvested plant material has been dried, cut, and is ready to be classified as stable, storable plant raw material—the raw flower in its stabilized form. From this point on, any additional processing steps (grinding, extraction, decarboxylation, standardization, formulation as an oil or capsule, and final packaging) fall under GMP.

One point deserves clarification, because in the case of cannabis, the «finished product» is sometimes simply the dried flower itself, sold as is for vaporization, rather than being processed into an extract. In this case, the transition from GACP to GMP occurs earlier than it does for cannabis oil: even seemingly simple steps (final drying to a precise pharmaceutical moisture content, grinding into a homogeneous product, and primary packaging for dispensing) are generally subject to GMP oversight, since the flower itself constitutes the dosage form given to the patient.

The European Medicines Agency (EMA) has, in fact, published specific FAQs on this exact distinction as it applies to ground plants and plant extracts used as active ingredients, precisely because the distinction is not always intuitive.

The safest working assumption for a vertically integrated producer remains the following: cultivation, drying, and aging fall under GACP; everything that follows (final processing and packaging) falls under GMP.

Which countries require it?

The GACP serves as a virtually universal foundation in most legal medical cannabis markets around the world; it is not unique to Europe.

Countries with established or emerging medical cannabis programs—particularly in Latin America, Africa, and certain regions of Asia—are increasingly requiring GACP-certified cultivation as a minimum condition for authorization, even when GMPs for finished products are not yet mandatory.

European GMPs, on the other hand, are much more geographically limited. They are a legal requirement in 27 EU Member States for any cannabis-based drug or raw material intended to be used in the manufacture of a finished pharmaceutical product marketed within the European Union.

Germany, currently Europe's largest market for medical cannabis, strictly enforces this requirement through its Ordinance on the Manufacture of Medicines and Active Substances (AMWHV), in addition to the European framework.

France, the Netherlands, Poland, Portugal, and other Member States with active or emerging medical cannabis programs all enforce the same European GMP requirements for any product entering their territory as a medication.

The United Kingdom, although it is no longer a member of the EU, maintains a British GMP framework that is very similar to the European one; in practice, most sites certified under European GMP are recognized as compliant with British requirements, and vice versa, under the mutual recognition agreements currently in effect.

Outside of Europe, some countries have negotiated Mutual Recognition Agreements (MRAs) with the EU, under which their national GMP inspections are considered equivalent, thereby reducing duplicate audits for exporters. The Canadian GPP framework, however, is not included in this list: Canadian exporters targeting the EU must obtain separate European GMP certification rather than relying on their national license.

For countries without equivalents to European GMP standards—particularly most of the United States, where cannabis remains illegal at the federal level and where regulation falls under state jurisdiction based on food safety or dietary supplement standards—access to the European medical market is effectively closed, unless a facility is independently certified to meet European GMP standards.

Why This Matters to the Industry

Beyond mere regulatory compliance, GACP and European GMP certification has become a true competitive differentiator. GMP-certified cannabis consistently commands a higher price than products certified only under GACP, and opens the door to public tenders, distribution through pharmacies, and cross-border exports—all opportunities that remain off-limits to non-certified operations.

As European regulators tighten their import requirements, with several Member States already indicating that GACP-certified imports alone will no longer suffice to meet pharmaceutical-grade supply needs, the pressure on growers and processors to obtain full European GMP certification—rather than just GACP—continues to intensify.

For the patient, this two-tiered system boils down to one simple fact: whether it’s dried flowers or standardized oil, GACP and GMP together form the quality framework that ensures what ends up on the pharmacy shelf is exactly what the label says: consistent, traceable, and free of contaminants—from seed to prescription.